You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation
|
|---|---|
| Published in |
Current opinion in cardiology, July 2012
|
| DOI | 10.1097/hco.0b013e3283540857 |
| Pubmed ID | |
| Authors |
Aaron Liew, John W. Eikelboom, Martin O’Donnell |
| Abstract |
The prevalence of atrial fibrillation is increasing because of an aging population. Vitamin K antagonists have been the standard therapy for stroke prevention in atrial fibrillation but are underutilized and often poorly managed because of their inherent limitations. This study critically reviews the recently completed phase 3 randomized controlled trials of new oral anticoagulants (OACs) for stroke prevention in patients with nonvalvular atrial fibrillation: RE-LY (dabigatran), AVERROES (apixaban), ARISTOTLE (apixaban) and ROCKET-AF (rivaroxaban). |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 72 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 3% |
| Slovenia | 1 | 1% |
| Colombia | 1 | 1% |
| Spain | 1 | 1% |
| Denmark | 1 | 1% |
| Unknown | 66 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 14 | 19% |
| Researcher | 11 | 15% |
| Student > Bachelor | 11 | 15% |
| Student > Ph. D. Student | 9 | 13% |
| Student > Postgraduate | 6 | 8% |
| Other | 16 | 22% |
| Unknown | 5 | 7% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 48 | 67% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Social Sciences | 3 | 4% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 4 | 6% |
| Unknown | 6 | 8% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 December 2012.
All research outputs
#20,656,161
of 25,374,647 outputs
Outputs from Current opinion in cardiology
#768
of 1,378 outputs
Outputs of similar age
#138,232
of 176,748 outputs
Outputs of similar age from Current opinion in cardiology
#4
of 18 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,378 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.1. This one is in the 2nd percentile – i.e., 2% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 176,748 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.